Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038 |
Resumo: | Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs. |
id |
RCAP_5a1cd0662a8e3c45b2fcb6bb7f76e34e |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/2038 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological MyopiaAvaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia PatológicaIntroduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.Introdução: A neovascularização coroideia associada à miopia patológica é uma das principais causas de perda de visão central e irreversível em indivíduos jovens. Os objetivos deste estudo são avaliar os resultados a longo prazo do tratamento antiangiogénico, com ranibizumab e/ou bevacizumab, na neovascularização coroideia associada à miopia patológica e caraterizar os fatores preditivos dos resultados funcionais e anatómicos obtidos.Material e Métodos: Avaliámos os resultados de 84 olhos de 81 doentes com neovascularização coroideia miópica, dos quais 84 (100%) completaram 12 meses de seguimento, 67 (79,8%) 24 meses de seguimento, 54 (64,3%) 36 meses de seguimento, 29 (34,5%) 48 meses de seguimento e 15 (16,7%) 60 meses de seguimento. Procedemos à recolha de dados relativos à melhor acuidade visual corrigida em escala ETDRS, espessura foveal na tomografia de coerência óptica e caraterísticas da angiografia fluoresceínica, inicial e após tratamento.Resultados: As melhorias na melhor acuidade visual corrigida e na espessura foveal foram significativas para todos os tempos de seguimento (p < 0,05). A média da melhor acuidade visual corrigida inicial era de 43,7 ± 20,1 letras e da espessura foveal inicial de 304,8 ± 127,9μm. As médias da melhor acuidade visual corrigida foram de 55,6 ± 18,5, 52,1 ± 22,3, 52,1 ± 22,6, 50,3 ± 23,8 e 47,8 ± 24,5 para os 12, 24, 36, 48 e 60 meses de tratamento, respetivamente. As médias das espessuras foveais foram de 209,7 ± 86,2, 190,6 ± 76,1, 174,7 ± 60,6, 189,8 ± 96,7 e 159,4 ± 73,3 para os mesmos tempos de seguimento. Apenas a melhor acuidade visual corrigida inicial foi preditiva de melhores resultados na melhor acuidade visual corrigida final (p < 0,001).Discussão/Conclusão: As injecções intravítreas de anti-VEGF em doentes com neovascularização coroideia miópica cursam com uma melhoria funcional e anatómica significativa e sustentada no tempo. Ensaios clínicos randomizados com follow-up mais extenso são necessários para comprovar a eficácia sustentada destes agentes.Ordem dos Médicos2014-01-08info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038oai:ojs.www.actamedicaportuguesa.com:article/2038Acta Médica Portuguesa; Vol. 27 No. 1 (2014): January-February; 49-58Acta Médica Portuguesa; Vol. 27 N.º 1 (2014): Janeiro-Fevereiro; 49-581646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038/3872https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038/3959Carvalho, BeatrizFreitas-Costa, PauloPinheiro-Costa, JoãoFalcão, ManuelCarneiro, ÂngelaFalcão-Reis, Fernandoinfo:eu-repo/semantics/openAccess2022-12-20T10:59:42Zoai:ojs.www.actamedicaportuguesa.com:article/2038Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:31.557760Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica |
title |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
spellingShingle |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia Carvalho, Beatriz |
title_short |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
title_full |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
title_fullStr |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
title_full_unstemmed |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
title_sort |
Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia |
author |
Carvalho, Beatriz |
author_facet |
Carvalho, Beatriz Freitas-Costa, Paulo Pinheiro-Costa, João Falcão, Manuel Carneiro, Ângela Falcão-Reis, Fernando |
author_role |
author |
author2 |
Freitas-Costa, Paulo Pinheiro-Costa, João Falcão, Manuel Carneiro, Ângela Falcão-Reis, Fernando |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Carvalho, Beatriz Freitas-Costa, Paulo Pinheiro-Costa, João Falcão, Manuel Carneiro, Ângela Falcão-Reis, Fernando |
description |
Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-01-08 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038 oai:ojs.www.actamedicaportuguesa.com:article/2038 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/2038 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038/3872 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2038/3959 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 27 No. 1 (2014): January-February; 49-58 Acta Médica Portuguesa; Vol. 27 N.º 1 (2014): Janeiro-Fevereiro; 49-58 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130628444127232 |